摘要：Rare neurodegenerative diseases are fatal and no therapy is available to cure or slow down
the progression of disease. We report possibly weaknesses in the management of clinical studies in
these diseases, ranging from poor preclinical studies, difficulties in the recruitment of patients, delay
in the onset of treatment because of lack in early disease-specific biomarkers, and suboptimal design
of Phase II clinical trials. The adoption of innovative statistical approaches in early Phase II trials
might improve the screening of drugs in rare neurodegenerative disorders, but this implicates efforts
from clinical researchers, statisticians, and regulatory people to the development of new strategies
that should maintain rigorous scientific integrity together with a more ethical approach to human
experimentations.
